The Role of Nutraceuticals in Statin Intolerant Patients

Banach, M. and Patti, A. M. and Giglio, R. V. and Cicero, A. F. G. and Atanasov, A. G. and Bajraktari, G. and Bruckert, E. and Descamps, O. and Djuric, D. M. and Ezhov, M. and Fras, Z. and von Haehling, S. and Katsiki, N. and Langlois, M. and Latkovskis, G. and Mancini, G. B. J. and Mikhailidis, D. P. and Mitchenko, O. and Moriarty, P. M. and Muntner, P. and Nikolic, D. and Panagiotakos, D. B. and Paragh, G. and Paulweber, B. and Pella, D. and Pitsavos, C. and Reiner, Ž and Rosano, G. M. C. and Rosenson, R. S. and Rysz, J. and Sahebkar, A. and Serban, M. C. and Vinereanu, D. and Vrablík, M. and Watts, G. F. and Wong, N. D. and Rizzo, M. and International Lipid Expert, Panel (2018) The Role of Nutraceuticals in Statin Intolerant Patients. Journal of the American College of Cardiology, 72 (1). pp. 96-118.

[img] Text
The Role of Nutraceuticals in Statin Intolerant Patients.pdf

Download (734kB)


Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. © 2018 American College of Cardiology Foundation

Item Type: Article
Additional Information: (ILEP) Cited By :48 Export Date: 16 February 2020 CODEN: JACCD Correspondence Address: Banach, M.; Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, 90-549, Poland; email:
Uncontrolled Keywords: cardiovascular risk dyslipidemia nutraceuticals position paper statin intolerance berberine bergamot oil C reactive protein hydroxymethylglutaryl coenzyme A reductase inhibitor isoflavone derivative low density lipoprotein cholesterol nutraceutical phytosterol soluble fiber unclassified drug artichoke cardiovascular disease clinical effectiveness drug hypersensitivity garlic human lipid metabolism low density lipoprotein cholesterol level lupin priority journal pulse wave Review tea clinical study diet therapy dietary supplement Clinical Studies as Topic Dietary Supplements Dyslipidemias Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors
Subjects: WG Cardiovascular System
QV pharmacology
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 02 Jun 2020 07:38
Last Modified: 02 Jun 2020 07:38

Actions (login required)

View Item View Item